Santaris Pharma - Gilde Healthcare

Santaris Pharma


Hørsholm, Denmark
San Diego, CA, USA

RNA-targeted Therapies
Since: 2007
Exit: 2014

Santaris Pharma discovers and develops RNA-targeted therapies to treat infectious diseases and metabolic disorders. Through its partnerships with pharmaceutical companies, Santaris covers a range of therapeutic areas including cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders.

Since Gilde invested in Santaris Pharma, the company has advanced its product pipeline through the clinic and signed commercial collaboration agreements with GlaxoSmithKline, Pfizer, Bristol-Myers Squibb, Roche and Shire. Santaris Pharma was acquired by Roche in 2014 for $450M.

Continue reading on Locked Nucleic Acid (LNA) Platform